Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.15 USD | -0.09% | +0.63% | -23.42% |
Apr. 19 | Pieris Pharmaceuticals Shares Fall After 1-for-80 Reverse Stock Split Announcement | MT |
Apr. 03 | North American Morning Briefing : Powell Awaited -2- | DJ |
Financials (USD)
Sales 2022 | 25.9M | Sales 2023 | 42.81M | Capitalization | 17.99M |
---|---|---|---|---|---|
Net income 2022 | -33M | Net income 2023 | -24M | EV / Sales 2022 | 1.21 x |
Net cash position 2022 | 46.07M | Net cash position 2023 | 26.37M | EV / Sales 2023 | -0.2 x |
P/E ratio 2022 |
-2.32
x | P/E ratio 2023 |
-0.67
x | Employees | 48 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.57% |
Latest transcript on Pieris Pharmaceuticals, Inc.
1 day | -0.09% | ||
1 week | +0.63% | ||
Current month | -4.78% | ||
1 month | -21.39% | ||
3 months | -15.53% | ||
6 months | -42.34% | ||
Current year | -23.42% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Yoder
CEO | Chief Executive Officer | 48 | 09-12-31 |
Thomas Bures
DFI | Director of Finance/CFO | 49 | 17-11-30 |
Kayti Aviano
CTO | Chief Tech/Sci/R&D Officer | - | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 59 | 16-09-19 | |
James Geraghty
CHM | Chairman | 69 | 17-05-21 |
Michael Richman
BRD | Director/Board Member | 63 | 14-12-16 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 11.15 | -0.09% | 8,554 |
24-05-09 | 11.16 | +0.18% | 2,146 |
24-05-08 | 11.14 | +0.91% | 8,944 |
24-05-07 | 11.04 | -0.18% | 10,745 |
24-05-06 | 11.06 | -0.18% | 17,050 |
Delayed Quote Nasdaq, May 10, 2024 at 04:30 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-23.42% | 13.79M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- PIRS Stock